AVPR2 and autosomal dominant polycystic kidney disease: Nephroprotective effects of V2R antagonists such as tolvaptan has been increasingly recognized, which led to their clinical approval as a part of therapy in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (58).